Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Invest in health impact assessment

Susann Roth, senior social development specialist, Asian Development Bank, argues why a health impact assessment is essential for hard infrastructure projects.

Although I am a medical doctor, I changed my career from a clinician in surgery to public health because I wanted to have impact on people’s lives by preventing diseases, instead of treating sickness, as I would often see patients when it was too late.

The “where” and “how” we live determines our health. We all agree with this. We all want a healthy future for ourselves and for our children. Looking at the bigger picture, we know that sustainable economic development needs healthy populations – especially in this part of the world.

But health is often not valued until it’s too late, when sickness comes. The same occurs in development projects.

Developing Asia is at a crossroads. The region’s rapid economic growth comes with concerns over environmental degradation. Around 27% of diseases affecting Asians are related to the environment, according to the World Health Organization. Throughout Asia’s cities, hundreds of millions of children are exposed to air quality that is dangerous for their health.

Infrastructure projects can affect human health in many ways, creating both risks and opportunities.

For many Asian developing countries, economic development is still based on heavy industry and investments in hard infrastructure that often don’t consider the long-term impacts on human health.

Water contamination with industrial or agricultural waste such as heavy metals, pesticides, and antibiotics can cause hormonal diseases and even cancer. Threats may happen prior or during project implementation, and even long after project termination.

However, unlike environment and resettlement, health is not a traditional safeguard in development projects. It does not get the attention it deserves to ensure that whatever is built contributes to healthier and better lives for everybody.

The best way to think of health during each stage of development is through a health impact assessment (HIA).

Along with sound public health management plans and effective monitoring and mitigation systems, HIA is of utmost importance for preventing and reducing the potential negative health impacts of such projects.

HIA is an established evidence-based method for showing what are otherwise the hidden costs and benefits of infrastructure projects to human health and to the heath sector in general. It is a structured process that combines scientific evidence and community engagement to inform decision-makers about how they can maximize the health benefits and minimize the adverse health impacts of infrastructure development projects.

HIA does not look only at environmental health impacts, but rather assesses community health as a whole. It aims to ensure that benefits of development can be shared more equitably across all affected communities.

It’s important to note that HIA targets in particular the vulnerable groups that carry the brunt of the negative health impacts of development. This reflects the “leave no-one behind” philosophy of the Sustainable Development Goals.

HIA, though, doesn’t come without challenges. For instance, one of the main reasons a health component is often omitted from infrastructure cost-benefit analysis is because of the inherent difficulties in measuring health outcomes. The Disability Adjusted Life Year or DALY, a metric of the disease burden affecting community health, remains poorly accepted outside of the health sector. 

Quantification is usually limited to health outcomes that can be expressed in terms of exposure and disease (dose/response), such as for air or water pollution. Moreover, changes in population health cannot usually be attributed to any single project alone: the longer the trajectory between cause and outcome, the more confounding factors will obscure the cause-effect relationship.

While HIA cannot always draw a straight line between an infrastructure project and a specific health outcome for a defined community, it can ensure that health is on the agenda when the impact of a project is being determined. HIA can also create explicit opportunities to enhance positive health impacts and to avoid, reduce, or mitigate adverse health impacts.

For this to happen, we need to implement three paradigm shifts. First we need to develop more ambitious regional and national level policies and guidelines for HIA. We need to do more than the bare minimum required for HIA in environmental impact assessments. For example, ADB is currently assisting Greater Mekong Subregion (GMS) countries to strengthen HIA policies and guidelines.

Second we must invest in capacity development of communities, civil society, and academia to generate the evidence to support the hypothesis that the cost of not conducting HIA is more expensive in the long term. To help GMS countries achieve this goal, ADB has trained more than 600 experts from public health, environment agencies, academia and private sector on HIA and created an HIA network across the subregion.

And third, we must mobilise more resources for HIA demonstration projects and to implement public health management plans that ensure infrastructure projects have the best possible health outcomes. ADB is working on several demonstration projects that showcase HIA in various sectors throughout the GMS.

Posted on: 15/01/2018 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.